Glaucoma | Ophthalmology Innovation Source

Alcon Makes Big Move in MIGS

With Transcend, Alcon Gains a Foothold in Glaucoma Device Market Contributed by Larry Haimovitch and Richard Mark Kirkner With its move to acquire Transcend Medical and its CyPass Micro-Stent platform for glaucoma, Novartis aims to kick start the lackluster growth of its Alcon unit by tapping into the high-growth micro-invasive glaucoma surgery (MIGS) device market…

How MIGS is Remaking the Glaucoma Market

Glaucoma is a chronic degenerative disease whose incidence increases significantly with age. According to the World Health Organization, it is the second leading cause of blindness in the world. Estimates put the total number of suspected cases of glaucoma at over 60 million worldwide. Glaucoma medications, which generate about $5 billion in annual sales globally,…

Glaucoma Getting a Wake-Up Call

SAN FRANCISCO — Thanks to a pending boom in minimally invasive glaucoma surgery (MIGS) devices, the global glaucoma device market is poised to come out of its long slumber and triple over the next five years, participants at the fifth annual “Glaucoma 360-New Horizons Forum” heard. Sponsored by the non-profit Glaucoma Research Foundation, the forum…

Inotek’s Southwell & McVicar Have Designs on Treating Glaucoma

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 070″] Inotek CEO David Southwell and William K. McVicar PhD Executive Vice President, Chief Scientific Officer, share Inotek’s plan to bring to market a new first-line for glaucoma sufferers. Podcast Guest David P. Southwell Mr. Southwell has been President and CEO since August 2014, and led Inotek through its IPO and…

Saunders Seen As Key Man in Pfizer-Allergan Mashup

Last week, Pfizer and Allergan executives gave us a lot to chew on over the Thanksgiving weekend. The $160 billion combination will create the world’s largest pharmaceutical company, a behemoth comprising at least one element – Allergan – that has had a significant interest in ophthalmology. Allergan – the new Allergan that emerged from the…

MicroOptx Pursues New MIGS Approach

Chris Pulling, CEO of MicroOptx, tells OISTV about its Brown Glaucoma Implant (new name pending). The implant is used to lower IOP by draining aqueous fluid. Unlike other implants, which divert fluid to other chambers of the eye, MicroOptx is shunts the fluid to the tear film. Speaking With: Chris Pulling Chris was most recently…

IOPtima Getting Traction in Europe, Asia

IOPtima CEO Ronan Castro gives OISTV an update on the company’s commerical launch of the IOPtimate system in Europe and Asia, including operations in China and Hong Kong. OPtima has developed the IOPtimate system; a unique laser based surgical system for the treatment of Glaucoma. The system utilizes a CO2 laser technology to reduce internal…

Inotek Pharmaceuticals

David P. Southwell, president and CEO of Inotek Pharmaceuticals, spelled out the focus of his clinical-stage biopharmaceutical firm in no uncertain terms at OIS@AAO. “Inotek is focused on glaucoma,” he said. “Clearly the optimal eyedrop to treat glaucoma would be one that both lowers intraocular pressure (IOP) in a well-tolerated fashion and is also neuroprotective.”…

Aerie Pharmaceuticals

Rhopressa is a Rho-kinase inhibitor that increases the outflow of the trabecular meshwork by relaxing it. It’s also a norepinephrine transport inhibitor that decreases the amount of fluid being produces, and drops episcleral venous pressure. Aerie has completed two phase III trials, with the Rocket 2 data being used to file the NDA for the…

Implandata

Implandata Ophthalmic Products GmbH (IOP GmbH), located in Hanover/Germany, is destined to transform management of glaucoma patients via a unique solution for early detection of elevated intraocular pressure (IOP), for reliable IOP patient self-measurement, for vastly improved disease monitoring and glaucoma therapy and for more efficient remote patient care. www.implandata.com Participant: Max G. Ostermeier, MBA…

ForSight VISION5

The company is addressing non-adherence to eyedrops in glaucoma and in ocular hypertension. There remains a true, unmet need to provide clinically relevant intraocular pressure (IOP) reduction with a simple non-invasive product for patients who do not or cannot take their medications. ForSIGHT has developed Helios, a soft, preservative-free ring infused with bimataprost that is…

Envisia Therapeutics

This company, founded as a spin-out of Liquidia Technologies in 2013, began with a $25 million Series A, with the goal of developing the PRINT particle platform for ophthalmic indications. The PRINT platform can be applied to make “very precise drug delivery systems for the eye,” Dr. Yerxa said, as anything that can be manufactured…